These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4609765)

  • 1. 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26)--a brief review.
    Goldsmith MA; Carter SK
    Eur J Cancer (1965); 1973 Jul; 9(7):477-82. PubMed ID: 4609765
    [No Abstract]   [Full Text] [Related]  

  • 2. Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas.
    Mathé G; Schwarzenberg L; Pouillart P; Oldham R; Weiner R; Jasmin C; Rosenfeld C; Hayat M; Misset JL; Musset M; Schneider M; Amiel JL; De Vassal F
    Cancer; 1974 Oct; 34(4):985-92. PubMed ID: 4608026
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms.
    Sklansky BD; Mann-Kaplan RS; Reynolds AF; Rosenblum ML; Walker MD
    Cancer; 1974 Feb; 33(2):460-7. PubMed ID: 4812764
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical screening of epipodophyllotoxin VM26 in malignant lymphomas and solid tumours.
    Br Med J; 1972 Jun; 2(5816):744-8. PubMed ID: 4556544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).
    Muggia FM; Selawry OS; Hansen HH
    Cancer Chemother Rep; 1971 Dec; 55(5):575-81. PubMed ID: 4946082
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition by 4'-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle.
    Misra NC; Roberts DW
    Cancer Res; 1975 Jan; 35(1):99-105. PubMed ID: 1053697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic trials in various hematosarcomas with 4-demethylepipo=dophyllotoxin-beta D thenylidene glucoside (VM 26 or EPT)].
    Mathé G; Schwarzenberg L; Pouillart P; Weiner R; Oldham R; Jasmin C; Rosenfeld ; Hayat M; Schneider M; Amiel JL; Céoara B; Steresco-Musset M; de Vassal F
    Nouv Presse Med; 1974 Feb; 3(8):447-51. PubMed ID: 4595690
    [No Abstract]   [Full Text] [Related]  

  • 8. VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors.
    Mechl Z; Rovný F; Sopková B
    Neoplasma; 1977; 24(4):411-4. PubMed ID: 904743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).
    Nissen NI; Larsen V; Pedersen H; Thomsen K
    Cancer Chemother Rep; 1972 Dec; 56(6):769-77. PubMed ID: 4634038
    [No Abstract]   [Full Text] [Related]  

  • 10. A quantitative microdensitometric and autoradiographic study of the effect of 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside (VM-26) on the cell cycle of cultured fibroblasts.
    Gotzos V; Cappelli-Gotzos B; Despond JM
    Histochem J; 1979 Nov; 11(6):691-707. PubMed ID: 536243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.
    European Organization for Research on the Treatment of Cancer, Clinical Screening Group
    Br Med J; 1973 Jul; 3(5873):199-202. PubMed ID: 4578134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute leukemia and various hematosarcomas. Trial treatment with a second derivative of podophyllotoxin (4-demethyl-epipodophyllotoxin beta D ethylidene glucoside VP 16213 or EPE)].
    Mathé G; Schwarzenberg L; Pouillart P; Weiner R; Oldham R; Jasmin C; Rosenfeld C; Hayat M; Schneider M; Amiel JL; Céoara B; Steresco-Musset M; de Vassal F
    Nouv Presse Med; 1974 Mar; 3(9):521-4. PubMed ID: 4595555
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience with 4'-demethylepipodo-phyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis.
    Sonntag RW; Senn HJ; Nagel G; Giger K; Alberto P
    Eur J Cancer (1965); 1974 Feb; 10(2):93-8. PubMed ID: 4611772
    [No Abstract]   [Full Text] [Related]  

  • 14. A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.
    Falkson G; van Dyk JJ; van Eden EB; van der Merwe AM; van den Bergh JA; Falkson HC
    Cancer; 1975 Apr; 35(4):1141-4. PubMed ID: 163675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
    Jankowski RP; Vahrson H
    Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners.
    Loike JD; Brewer CF; Sternlicht H; Gensler WJ; Horwitz SB
    Cancer Res; 1978 Sep; 38(9):2688-93. PubMed ID: 679171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell.
    Allen LM
    Cancer Res; 1978 Aug; 38(8):2549-54. PubMed ID: 667850
    [No Abstract]   [Full Text] [Related]  

  • 18. 4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action.
    Stähelin H
    Eur J Cancer (1965); 1970 Aug; 6(4):303-11. PubMed ID: 4991932
    [No Abstract]   [Full Text] [Related]  

  • 19. VM 26 and VP 16-213: a comparative analysis.
    Rozencweig M; Von Hoff DD; Henney JE; Muggia FM
    Cancer; 1977 Jul; 40(1):334-42. PubMed ID: 328129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.
    Dombernowsky P; Nissen NI; Larsen V
    Cancer Chemother Rep; 1972 Feb; 56(1):71-82. PubMed ID: 4624138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.